Novo Nordisk optimistic about entering MASH treatment market with semaglutide, potential boost in value

From Investing.com: 2024-12-19 11:30:00

Recent sales growth for Novo Nordisk’s GLP-1 agonist drugs, Ozempic and Wegovy, has been strong, with increases of 32% and 76% in the first nine months of 2024 compared to the same period in 2023. However, the stock has only provided a 5% total return for the year due to competition from Eli Lilly’s Zepbound, which has shown stronger weight loss results. Novo is now looking to enter the lucrative MASH treatment market with semaglutide, which could potentially boost its value and market share.

With Novo Nordisk facing challenges from Eli Lilly’s Zepbound, the company is now looking to expand into the MASH treatment market with semaglutide. Recent data shows that semaglutide could be more effective than Rezdiffra, the current MASH treatment, pointing towards a potential advantage for Novo in this market. Novo plans to seek regulatory approval for semaglutide to treat MASH in 2025, which could help change the narrative around the drug and improve its market position.



Read more at Investing.com: Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon